Cleveland Clinic offers smoking cessation programs. Eat a balanced diet that is high in fiber and low in cholesterol, fat and sodium. Limit fat to 30 percent of your total daily calories. Saturated fat should account for no more than 7 percent of your total calories. Avoid trans fats including products made with partially-hydrogenated and hydrogenated vegetable oils. If you are overweight, losing weight will help you lower your total cholesterol and raise your HDL good cholesterol. A registered dietitian can help you make the right dietary changes. Begin a regular exercise program, such as walking.
Walking is very important and can aid the treatment of PAD. Patients who walk regularly can expect a marked improvement in the distance they are able to walk before experiencing leg pain. Ask your doctor if your hospital or clinic offers a structured, supervised walking program to help you succeed and maximize your exercise efforts. Manage other related health problems, such as high blood pressure , diabetes , or high cholesterol.
Medications May be recommended to treat conditions such as high blood pressure anti-hypertensive medications or high cholesterol statin medications. An antiplatelet medication such as aspirin or clopidogrel Plavix may be prescribed to reduce the risk of heart attack and stroke. Often, patients may be prescribed both of these medications to reduce the risk of cardiovascular complications such as heart attack or stroke. Cilostazol Pletal may be prescribed to improve walking distance. This medication has been shown to help some people with intermittent claudication exercise longer before they develop leg pain and to walk longer before they must stop because of the pain.
Intracranial Atherosclerotic Disease
Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. USA 92 , — Martinod, K. Thrombosis: tangled up in NETs. Blood , — Franck, G. Folco, E. Bevilacqua, M. Regulation of the fibrinolytic system of cultured human vascular endothelium by IL Time-dependent changes in atherosclerotic plaque composition in patients undergoing carotid surgery.
Quillard, T. Mechanisms of erosion of atherosclerotic plaques. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion. Flow perturbation mediates neutrophil recruitment and potentiates endothelial injury via TLR2 in mice: implications for superficial erosion. Fernandez-Friera, L. Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle-aged cohort: the PESA Progression of Early Subclinical Atherosclerosis study.
Doukky, R. Promoting appropriate use of cardiac imaging: no longer an academic exercise. Gould, K. Effects of coronary stenoses on coronary flow reserve and resistance. Rumberger, J.
- Worlding Women: A Feminist International Politics.
- US Withholding Tax: Practical Implications of QI and FATCA.
- Atherosclerosis Treatment With Modern Lipid-Lowering Drugs.
- Words without Objects: Semantics, Ontology, and Logic for Non-Singularity?
- Interferons Part A.
- Arteriosclerosis / atherosclerosis - Diagnosis and treatment - Mayo Clinic.
Mayo Clin. Topol, E. Our preoccupation with coronary luminology. The dissociation between clincial and angiographic findings in ischemic heart disease. Circulation 92 , — Tonino, P. Angiographic versus functional severity of coronary artery stenoses in the fame study. Falk, E. Coronary plaque disruption. Bittencourt, M.
Prognostic value of nonobstructive and obstructive coronary artery disease detected by coronary computed tomography angiography to identify cardiovascular events. Maddox, T. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA , — Wilson, J. Principles and practice of mass screening for disease [article in Spanish].
Oficina Sanit. Piepoli, M. Goff, D. Circulation , S49—S73 Stone, N. Circulation , S1—S45 Nasir, K. Sabatine, M. Evolocumab and clinical outcomes in patients with cardiovascular disease. Antiinflammatory therapy with canakinumab for atherosclerotic disease. Eikelboom, J. Rivaroxaban with or without aspirin in stable cardiovascular disease. Global, regional, and national burden of cardiovascular diseases for 10 causes, to Heidenreich, P. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association.
McConnachie, A. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. Lloyd-Jones, D. Falaschetti, E. Adiposity and cardiovascular risk factors in a large contemporary population of pre-pubertal children. Victora, C. Maternal and child undernutrition: consequences for adult health and human capital. Juonala, M. Childhood adiposity, adult adiposity, and cardiovascular risk factors. Vedanthan, R. Family-based approaches to cardiovascular health promotion. Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps.
Pahkala, K. Koskinen, J. Arterial structure and function after recovery from the metabolic syndrome. Tonetti, M. Treatment of periodontitis and endothelial function. Baena-Diez, J. Association between chronic immune-mediated inflammatory diseases and cardiovascular risk. Heart , — Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial. Lancet Diabetes Endocrinol. Marma, A. Distribution of year and lifetime predicted risks for cardiovascular disease in US adults: findings from the National Health and Nutrition Examination Survey to Berry, J.
Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease. Patel, R. Online self-assessment of cardiovascular risk using the Joint British Societies JBS3 -derived heart age tool: a descriptive study. BMJ Open 6 , e JBS3 Board. Heart Suppl. Lopez-Gonzalez, A. Kivipelto, M. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study.
Lancet Neurol. Gottesman, R. Midlife hypertension and year cognitive change: the atherosclerosis risk in communities neurocognitive study. JAMA Neurol. Rovio, S. Ngandu, T. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people FINGER : a randomised controlled trial. Turakhia, M. Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: the Apple Heart Study. Wilkins E. European Cardiovascular Disease Statistics European Heart Network, Moran, A.
Temporal trends in ischemic heart disease mortality in 21 world regions, to the Global Burden of Disease study. Mora, S.
You are here
Low-dose aspirin in the primary prevention of cardiovascular disease: shared decision making in clinical practice. Aspirin for primary prevention of atherosclerotic cardiovascular disease: advances in diagnosis and treatment. JAMA Intern. Dugani, S. Weighing the anti-ischemic benefits and bleeding risks from aspirin therapy: a rational approach. Should aspirin be used for primary prevention in the post-statin era? Raber, I. The rise and fall of aspirin in the primary prevention of cardiovascular disease.
Betsholtz, C. Nature , — Chow, C. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Law, M. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of randomised trials in the context of expectations from prospective epidemiological studies. BMJ , b Duckworth, W. Glucose control and vascular complications in veterans with type 2 diabetes. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from , participants in 26 randomised trials.
Collins, R. Interpretation of the evidence for the efficacy and safety of statin therapy. What works and in whom? A simple, easily applied, evidence-based approach to guidelines for statin therapy. Ridker P. Braunwald, E. Grundy, S. Di Angelantonio, E. Major lipids, apolipoproteins, and risk of vascular disease. Saely, C. Combination lipid therapy in type 2 diabetes. Department of Health and Human Services. Food and Drug Aministration. AbbVie Inc. Withdrawal of approval of indications related to the coadministration with statins in applications for niacin extended-release tablets and fenofibric acid delayed-release capsules.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from participants in 26 randomised trials.
Intracranial Atherosclerotic Disease | Michigan Medicine
The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. Hammersley, D. Chronic Dis. Cannon, C. Ezetimibe added to statin therapy after acute coronary syndromes. Robinson, J. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. Nicholls, S.
Cardiovascular efficacy and safety of bococizumab in high-risk patients. Ray, K. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. Landmesser, U. A masterful review of an important innovation in anti-atherosclerotic therapy with an emphasis on its practical application. Annemans, L. Clinical benefit of evolocumab by severity and extent of coronary artery disease. Bhatt, D. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. BMJ , 71—86 Zheng, S. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis.
Roffi, M. Interleukin-1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes and related leukocyte cell lines. Low-dose methotrexate for the prevention of atherosclerotic events. Nissen S. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis.
Ricciotti, E. Prostaglandins and inflammation. Benner JS, G. Long-term persistence in use of statin therapy in elderly patients. Kim, M. Impact of postdischarge statin withdrawal on long-term outcomes in patients with acute myocardial infarction. Zhang, H. Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study. Stroes, E. Newman, C.
Statin safety and associated adverse events: a scientific statement from the American Heart Association. Vaishnava, P. Assessment of quality of life in severe heart failure. Heart Fail. Mark, D. Assessing quality-of-life outcomes in cardiovascular clinical research. Muhammad, I. Narrative review of health-related quality of life and its predictors among patients with coronary heart disease. Lewis, E. Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study valsartan in acute myocardial infarction.
Thomas, S. Racial differences in the association between self-rated health status and objective clinical measures among participants in the BARI 2D trial. Public Health Suppl. Sajobi, T. Trajectories of health-related quality of life in coronary artery disease. Outcomes 11 , e De Smedt, D. Validity and reliability of three commonly used quality of life measures in a large European population of coronary heart disease patients.
- Federated Search Page Form block!
- Browse by Topic.
- Probabilistic Modelling in Bioinformatics and Medical Informatics.
- Browse by Topic.
- Congress and the income tax.
Hlatky, M. Kroenke, K. The PHQ validity of a brief depression severity measure. Kulik, A. Quality of life after coronary artery bypass graft surgery versus percutaneous coronary intervention: what do the trials tell us? Gomes-Neto, M.